AI Terminal
ARIX BIOSCIENCE PLC
Share Issue/Capital Change • Nov 13, 2023
4968_rns_2023-11-13_e2a03e2d-705d-4c7f-bf24-5efa24aa9bed.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
Arix Bioscience PLC (ARIX)
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
13-Nov-2023 / 16:00 GMT/BST
The following amendment has been made to the “Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock” announcement released on 10/11/2023 at 08:00 GMT under EQS News ID 1770215.
Some definitions of the “Company” have been amended to reflect the defined name of the portfolio company, “Aura”, throughout the release.
All other information remains unchanged. The fully amended text is shown below:
Arix Bioscience plc
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
LONDON, 13 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (NASDAQ: AURA) (“Aura”), has announced the closing of its underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share.
Aura received net proceeds from the Offering, after deducting the underwriting discounts and commissions and estimated offering expenses, of approximately $92.6 million. Aura intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities to advance the clinical development of belzupacap sarotalocan for the treatment of choroidal melanoma and choroidal metastasis, to develop the platform and for general corporate purposes. Aura believes that the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, will enable it to fund its operating expenses and capital expenditure requirements into the second half of 2026.
Arix holds 1,508,483 shares in Aura. The holding value of these shares will continue to be determined by the market price of Aura’s shares.
The full text from Aura’s announcement can be accessed on the Aura Biosciences website here: https://ir.aurabiosciences.com/press-releases
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
| ISIN: | GB00BD045071 |
| Category Code: | MSCM |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 284573 |
| EQS News ID: | 1772109 |
| End of Announcement | EQS News Service |